Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.1636
-0.0230 (-12.33%)
At close: Nov 20, 2026, 4:00 PM EST
0.1666
+0.0030 (1.83%)
After-hours: Nov 20, 2026, 7:46 PM EST
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $138.00K in the quarter ending September 30, 2026, a decrease of -46.51%. This brings the company's total for the last twelve months to $2.38M, up 230.37% year-over-year. In the fiscal year ending March 31, 2026, Vistagen Therapeutics had annual revenue of $1.27M with 161.11% growth. That makes Vistagen Therapeutics the 42,051st largest company in the world by revenue and 5,700th in the United States.
Revenue (ttm)
$2.38M
Revenue Growth
+230.37%
P/S Ratio
3.17
Revenue / Employee
$58,073
Employees
41
Market Cap
7.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.27M | 783.00K | 161.11% |
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | - |
| Mar 31, 2023 | -227.00K | -1.34M | - |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Mar 31, 2018 | - | - | - |
| Mar 31, 2017 | 1.25M | - | - |
| Mar 31, 2016 | - | - | - |
| Mar 31, 2015 | - | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | 200.40K | -1.14M | -85.07% |
| Mar 31, 2012 | 1.34M | -728.80K | -35.19% |
| Mar 31, 2011 | 2.07M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 33.65M |
| Radiopharm Theranostics | 8.90M |
| Immuron | 5.34M |
| BioLineRx | 1.39M |
| Lisata Therapeutics | 100.00K |
VTGN News
- 8 days ago - Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Vistagen Therapeutics Quarterly report: Q2 2027 - Filings
- 8 days ago - Vistagen Therapeutics Earnings release: Q2 2027 - Filings
- 12 days ago - Vistagen provides regulatory update following Type C meeting with the FDA - TheFly
- 12 days ago - Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder - GlobeNewsWire
- 4 weeks ago - Vistagen selects GATC Health to apply predictive AI to drug development - TheFly
- 4 weeks ago - Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs - GlobeNewsWire
- 1 month ago - SRX Global says adds investment in Onconetix - TheFly